Evidence map›Paper›PMID 29692733›Full record

ArticleFrontiers in pharmacology2018

Identification of Mepenzolate Derivatives With Long-Acting Bronchodilatory Activity.

Ken-Ichiro Tanaka, Naoki Yamakawa, Yasunobu Yamashita, Teita Asano, Yuki Kanda, Ayaka Takafuji, Masahiro Kawahara, Mitsuko Takenaga, Yoshifumi Fukunishi, Tohru Mizushima

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Ken-Ichiro TanakaResearch Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Musashino University, Nishi-Tokyo, Japan.
Naoki YamakawaSchool of Pharmacy, Shujitsu University, Okayama, Japan.
Yasunobu YamashitaMolecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.
Teita AsanoInstitute of Medical Science, School of Medicine, St. Marianna University, Kawasaki, Japan.
Yuki KandaResearch Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Musashino University, Nishi-Tokyo, Japan.
Ayaka TakafujiResearch Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Musashino University, Nishi-Tokyo, Japan.
Masahiro KawaharaResearch Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Musashino University, Nishi-Tokyo, Japan.
Mitsuko TakenagaInstitute of Medical Science, School of Medicine, St. Marianna University, Kawasaki, Japan.
Yoshifumi FukunishiMolecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.
Tohru MizushimaLTT Bio-Pharma Co., Ltd., Tokyo, Japan.
Musashino University · JPNational Institute of Advanced Industrial Science and Technology · JPSt. Marianna University School of Medicine · JPShujitsu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard treatment for chronic obstructive pulmonary disease is a combination of anti-inflammatory drugs and bronchodilators. We recently found that mepenzolate bromide (

Indexed as

anti-inflammatorychronic obstructive pulmonary diseaselong-acting bronchodilatory activitymepenzolate

Identifiers

PMID29692733
PMCPMC5902689
OpenAlexW2800550610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.